- Products
- Flow Cytometry
- Biotheraputics Discovery
- Custom Services
- Bioanalytical Antibodies
- Tools and Resources
- Antibody Support
- Order Status
- Quick Order
- Support
Browsing Modes for Business Users
-
Create mode – the default mode when you create a requisition and PunchOut to Bio-Rad. You can create and edit multiple shopping carts
-
Edit mode – allows you to edit or modify an existing requisition (prior to submitting). You will be able to modify only the cart that you have PunchedOut to, and will not have access to any other carts
-
Inspect mode – when you PunchOut to Bio-Rad from a previously created requisition but without initiating an Edit session, you will be in this mode. You cannot modify any Cart contents
Poster: Characterization of Anti-idiotypic Antibodies for High Performance in Bioanalytical Assays
- On This Page
- Poster Overview
- Order your printed copy below
-
Monoclonal Generation
-
Custom Recombinant Monoclonal Antibody Generation
-
Webinars, Videos and Technical Articles
- Webinar: Overcome the Challenges of PK Assay Development Using TrailBlazer Antibodies
- Webinar: Generation of SARS-CoV-2 antibodies in multiple formats within four weeks
- Webinar: Recombinant Antibodies with SpyTag Technology
- Webinar: Transform bioanalytical assays with TrailBlazer Antibodies
- Webinar: Control your critical antibody reagents and avoid assay failure
- Webinar: Improve your antibody drug development assays
- Webinar: Optimize your assays using recombinant antibodies selected for desired affinity
- Webinar: The making of recombinant anti-idiotypic antibodies for high performance in bioanalytical assays
- Webinar: Human recombinant antibodies as positive controls and calibrators
- Webinar: How to overcome assay challenges using custom recombinant antibodies
- Webinar: Generation of high affinity recombinant antibodies for application in immuno-MRM
- Video: Generating anti-idiotypic antibodies for bioanalytical assays
- Video: Best practices for characterization and QC of anti-idiotypic antibodies for bioanalysis
- Video: Generation of drug-target complex specific antibodies
- Video: Antibodies for CAR-T cell therapy development
- Article: Monitoring antibody immune responses against biotherapeutic drugs
- Article: Effective tools for drug monitoring assays
- Article: An accelerated approach to sensitive ADA assays
- Article: Isolation of enzyme active site-specific recombinant antibodies by guided selection
- Article: Biomarker Assay Development using Highly Specific Recombinant Antibodies
- Article: Recombinant antibodies as standards for immunodiagnostic assays
- Article: High affinity antibodies for peptide enrichment immuno-MRM
- Article: Generation of antibodies against self-antigens
- Article: Generation and characterization of drug-target complex-specific antibodies
- Article: Antibodies for CAR-T Cell Therapy Development
- Poster: Faster Generation of Anti-Drug Antibodies Using SpyTag Technology
- Poster: CAR T cell analysis with modular antibodies
- Poster: Drug-Target-Complex Specific Antibodies for Pharmacokinetic Analysis of Biotherapeutics
- Poster: Characterization of anti-idiotypic antibodies for high performance in bioanalytical assays
- Poster: Recombinant anti-idiotypic antibodies for antibody drug development
- Poster: Generation of recombinant antibodies for Bio-Plex assays
-
Webinars, Videos and Technical Articles
-
Custom Recombinant Monoclonal Antibody Generation
Follow us on:
Custom Antibody Project Inquiry Form
A personal, no obligation quotation for a custom monoclonal antibody generation project
This poster demonstrates how Bio-Rad applies industry recommended standards to characterize recombinant monoclonal anti-idiotypic antibodies that are manufactured and qualified for use in pharmacokinetic and anti-drug antibody assays.
- Quality control to ensure batch-to batch consistency
- Purity assessment of Fab antibodies and full immunoglobulins
- Accelerated stability and freeze-thaw testing
- Affinity determination
Read more about using HuCAL® technology to generate antibodies to biosimilars and novel biotherapeutics for the development of bioanalytical assays.
